IQVIA Holdings Inc. (NYSE:IQV) Holdings Boosted by Telos Capital Management Inc.

Telos Capital Management Inc. grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,747 shares of the medical research company’s stock after purchasing an additional 514 shares during the quarter. Telos Capital Management Inc.’s holdings in IQVIA were worth $9,182,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Versant Capital Management Inc boosted its stake in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the second quarter worth approximately $27,000. Park Place Capital Corp bought a new position in IQVIA in the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. acquired a new stake in IQVIA in the 2nd quarter valued at approximately $29,000. Finally, Riverview Trust Co bought a new stake in IQVIA during the 1st quarter valued at $32,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Price Performance

IQV stock opened at $231.22 on Tuesday. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The firm has a 50-day moving average of $239.07 and a two-hundred day moving average of $231.03. The firm has a market capitalization of $42.15 billion, a PE ratio of 30.03, a P/E/G ratio of 2.26 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter in the prior year, the firm earned $2.22 EPS. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. On average, analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on IQV. Royal Bank of Canada initiated coverage on IQVIA in a report on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price target on the stock. Barclays dropped their price target on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 15th. Robert W. Baird raised their price objective on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research note on Friday, September 20th. JPMorgan Chase & Co. increased their price target on IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a research note on Monday, August 5th. Finally, Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $267.87.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.